EGFR and osteosarcoma: Subsequently, the targetable genetic alterations of lung cancer have been gradually identified such as epidermal growth factor receptor (EGFR) mutations, kirsten rat sarcoma (KRAS) mutations and rat osteosarcoma (ROS1), and the development of targeted drugs greatly affected the prognosis of patients [11,12].